Aurobindo Pharma Ltd (BOM:524804)
₹ 1267.4 -20.45 (-1.59%) Market Cap: 736.11 Bil Enterprise Value: 739.33 Bil PE Ratio: 21.08 PB Ratio: 2.49 GF Score: 91/100

Q3 2023 Aurobindo Pharma Ltd Earnings Call Transcript

Feb 10, 2023 / 03:00AM GMT
Release Date Price: ₹468.8 (+6.38%)
Operator

Welcome to Aurobindo Pharma Q3 FY '23 Earnings Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to management for opening remarks. Thank you, and over to you.

Deepti Thakur

Thank you, Vandit. Good morning, and a warm welcome to our Third Quarter FY '23 Earnings Call. I am Deepti Thakur from the Investor Relations team. We hope you have received the Quarter 3 FY '23 financials and the press release that was sent out yesterday. These are also available on our website.

I would like to introduce my senior management team today on the call with us. Represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccines and Peptide Businesses; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialities Limited; Mr. Sanjeev Dani, COO and Head, Formulations, Aurobindo Pharma Limited; Mr. Swami Iyer, CEO Aurobindo Pharma USA; and Mr. S. Subramanian, CFO.

We will begin the call with summary highlights from the management followed by an interactive Q&A session. Please note that some of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot